Renaissance Technologies LLC boosted its position in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 63.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 650,100 shares of the biotechnology company’s stock after purchasing an additional 253,000 shares during the period. Renaissance Technologies LLC owned 1.45% of Pieris Pharmaceuticals worth $4,908,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. grew its position in Pieris Pharmaceuticals by 4.4% during the 4th quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock worth $12,053,000 after purchasing an additional 67,895 shares in the last quarter. State Street Corp purchased a new position in Pieris Pharmaceuticals during the 2nd quarter worth approximately $2,377,000. Arrowstreet Capital Limited Partnership purchased a new position in Pieris Pharmaceuticals during the 4th quarter worth approximately $3,370,000. Bogle Investment Management L P DE grew its position in Pieris Pharmaceuticals by 19.9% during the 4th quarter. Bogle Investment Management L P DE now owns 257,779 shares of the biotechnology company’s stock worth $1,946,000 after purchasing an additional 42,845 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Pieris Pharmaceuticals by 100.5% during the 4th quarter. Geode Capital Management LLC now owns 199,945 shares of the biotechnology company’s stock worth $1,509,000 after purchasing an additional 100,207 shares in the last quarter. Hedge funds and other institutional investors own 43.99% of the company’s stock.
Pieris Pharmaceuticals stock opened at $6.43 on Tuesday. Pieris Pharmaceuticals Inc has a 12 month low of $2.28 and a 12 month high of $9.75. The firm has a market cap of $346.29, a PE ratio of -16.08 and a beta of 1.71.
In other news, major shareholder Orbimed Advisors Llc sold 7,897 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total transaction of $70,915.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.05% of the company’s stock.
Several research firms have weighed in on PIRS. BidaskClub cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. ValuEngine upgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Evercore ISI initiated coverage on shares of Pieris Pharmaceuticals in a report on Monday, March 19th. They set an “outperform” rating and a $13.00 price target on the stock. Jefferies Group initiated coverage on shares of Pieris Pharmaceuticals in a report on Monday, March 19th. They set a “buy” rating and a $12.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Pieris Pharmaceuticals in a report on Friday, March 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $11.50.
ILLEGAL ACTIVITY WARNING: “Pieris Pharmaceuticals Inc (PIRS) Shares Bought by Renaissance Technologies LLC” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/04/17/pieris-pharmaceuticals-inc-pirs-shares-bought-by-renaissance-technologies-llc.html.
Pieris Pharmaceuticals Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.